UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  


  

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

  

Date of ReportFebruary 3, 2014

(Date of earliest event reported)

  

MRI Interventions, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 

000-54575 

58-2394628

(State or other jurisdiction

(Commission File

(I.R.S. Employer

of incorporation or organization)

Number)

Identification No.)

 

 

 

One Commerce Square, Suite 2550     

 

Memphis, Tennessee

38103

(Address of principal executive offices) 

(Zip Code)

 

 

(901) 522-9300

(Registrant's telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 7.01. Regulation FD Disclosure.

 

On February 3, 2014, David Carlson, Chief Financial Officer of MRI Interventions, Inc. (the “Company”), is electronically distributing a letter to stockholders of the Company, among other persons. Attached to that letter will be a newsletter that provides an abbreviated 2013 year-in-review with respect to the Company’s ClearPoint system. A copy of the letter, including the newsletter, is being furnished herewith as Exhibit 99.1. The newsletter includes active hyperlinks that are not accessible on Exhibit 99.1. However, the newsletter, with active hyperlinks, is available on the Company’s website at www.mriinterventions.com/clearpoint/clearpoint-newsletter.

 

The Company is furnishing the information contained in Exhibit 99.1 pursuant to Regulation FD. Such information is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

The information contained in Exhibit 99.1 is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make from time to time, by press release or otherwise. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.     

 

 

 

 

 Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits.

 

See Exhibit Index immediately following signature page.

 

 
2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MRI Interventions, Inc.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Oscar Thomas

 

 

 

Oscar Thomas

 

 

 

Vice President, Business Affairs

 

 

 

Date:

February 3, 2014

 

 
3

 

 

EXHIBIT INDEX

 

Exhibit No.

Description

 

 

99.1

Letter from David Carlson, Chief Financial Officer of MRI Interventions, Inc.

 

 

 

4